Phase III studies have demonstrated the clinical benefit of adding neo-adjuvant androgen deprivation to radical radiotherapy for clinically localised prostate cancer. We have developed a nomogram to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback